HRP20120912T1 - Derivati kinolina kao antibakterijska sredstva - Google Patents
Derivati kinolina kao antibakterijska sredstva Download PDFInfo
- Publication number
- HRP20120912T1 HRP20120912T1 HRP20120912TT HRP20120912T HRP20120912T1 HR P20120912 T1 HRP20120912 T1 HR P20120912T1 HR P20120912T T HRP20120912T T HR P20120912TT HR P20120912 T HRP20120912 T HR P20120912T HR P20120912 T1 HRP20120912 T1 HR P20120912T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- use according
- compound
- image
- formula
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims 7
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title claims 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 23
- 125000000217 alkyl group Chemical group 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 239000001257 hydrogen Substances 0.000 claims 16
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- -1 cyano, hydroxy Chemical group 0.000 claims 11
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- 150000002431 hydrogen Chemical group 0.000 claims 10
- 208000035143 Bacterial infection Diseases 0.000 claims 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims 8
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 8
- 150000001204 N-oxides Chemical class 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 3
- 241000191967 Staphylococcus aureus Species 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 3
- 239000003926 antimycobacterial agent Substances 0.000 claims 3
- 229960003085 meticillin Drugs 0.000 claims 3
- 125000004193 piperazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 241000191940 Staphylococcus Species 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- 206010062207 Mycobacterial infection Diseases 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 241000194017 Streptococcus Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002346 iodo group Chemical group I* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (37)
1. Uporaba spoja za proizvodnju lijeka za liječenje bakterijske infekcije, a navedeni spoj je spoj sa formulom (Ia) ili (Ib)
[image]
[image]
njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov N-oksid,
naznačen time da
R1 je vodik, halo, haloalkil, cijano, hidroksi, Ar, Het, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil ;
p je cijeli broj jednak 1, 2, 3 ili 4 ;
R2 je vodik, hidroksi, merkapto, alkiloksi, alkiloksialkiloksi, alkiltio, mono ili di(alkil)amino ili radikal sa formulom
[image]
pri čemu Y je CH2, O, S, NH ili N-alkil ;
R3 je alkil, Ar, Ar-alkil, Het ili Het-alkil;
q je cijeli broj jednak 1, 2 ili 3;
R4 i R5 svaki neovisno su vodik, alkil ili benzil; ili
R4 i R5 zajedno i uključujući N na kojeg su spojeni mogu tvoriti radikal koji je odabran iz skupine koja sadrži pirolidinil, 2-pirolinil, 3-pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piperidinil, piridinil, piperazinil, piridazinil, pirimidinil, pirazinil, triazinil, morfolinil i tiomorfolinil, proizvoljno supstituirani sa alkilom, halo, haloalkilom, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiloksialkilom, alkiltioalkilom ili pirimidinilom; R6 je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ili dva susjedna R6 radikala mogu zajedno tvoriti dvovalentni radikal sa formulom -CH=CH-CH=CH-;
r je cijeli broj jednak 1, 2, 3, 4 ili 5;
R7 je vodik, alkil, Ar ili Het;
R8 je vodik ili alkil;
R9 je okso; ili
R8 i R9 zajedno tvore radikal -CH=CH-N=;
alkil je ravno-lančani ili razgranati zasićeni radikal ugljikovodika koji ima 1 do 6 atoma ugljika; ili je ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 atoma ugljika; ili je ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 atoma ugljika koji su spojeni na ravno-lančani ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 atoma ugljika; pri čemu svaki atom ugljika može proizvoljno biti supstituiran sa hidroksi, alkiloksi ili okso;
Ar je homocikal koji je odabran iz skupine koja sadrži fenil, naftil, acenaftil, tetrahidronaftil, a svaki homocikal je proizvoljno supstituiran 1, 2 ili 3 supstituenta, od koji je svaki supstituent neovisno odabran iz skupine koja sadrži hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkil, haloalkil, alkiloksi, haloalkiloksi, karboksil, alkiloksikarbonil, aminokarbonil, morfolinil i mono- ili dialkilaminokarbonil;
Het je monociklički heterocikal koji je odabran iz skupine koja sadrži N-fenoksipiperidinil, piperidinil, pirolil, pirazolil, imidazolil, furanil, tienil, oksazolil, izoksazolil, tiazolil, izotiazolil, piridinil, pirimidinil, pirazinil i piridazinil; ili je biciklički heterocikal koji je odabran iz skupine koja sadrži kinolinil, kinoksalinil, indolil, benzimidazolil, benzoksazolil, benzizoksazolil, benzotiazolil, benzizotiazolil, benzofuranil, benzotienil, 2,3-dihidrobenzo[1,4]dioksinil i benzo[1,3]dioksolil; a svaki monociklički ili biciklički heterocikal može proizvoljno biti supstituiran sa 1, 2 ili 3 supstituenta, a svaki supstituent je neovisno odabran iz skupine koja sadrži halo, hidroksi, alkil, alkiloksi, te Ar-karbonil;
halo je supstituent koji je odabran iz skupine koja sadrži fluoro, kloro, bromo i jodo; i
haloalkil je ravno-lančani ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 atoma ugljika ili ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 atoma ugljika ili ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 atoma ugljika koji su spojeni na ravno-lančani ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 atoma ugljika; pri čemu su jedan ili više atoma ugljika supstituirani sa jednim ili više halo atoma;
pod uvjetom da je bakterijska infekcija različita od mikobakterijske infekcije.
2. Uporaba prema zahtjevu 1 naznačena time da spoj sa formulom (Ia) ili (Ib) je spoj koji ima slijedeću formulu
[image]
[image]
njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov N-oksid.
3. Uporaba prema zahtjevu 1 naznačena time da spoj sa formulom (Ia) ili (Ib) je spoj koji ima slijedeću formulu
[image]
[image]
njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov N-oksid.
4. Uporaba prema zahtjevu 1 naznačena time spoj da sa formulom (Ia) ili (Ib) je spoj koji ima slijedeću formulu
[image]
[image]
5. njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov N-oksid.
6. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R1 je vodik, halo, Ar, Het ili alkil.
7. Uporaba prema zahtjevu 5 naznačena time da R1 je vodik, halo, Ar ili Het.
8. Uporaba prema zahtjevu 6 naznačena time da R1 je halo ili Het.
9. Uporaba prema zahtjevu 7 naznačena time da R1 je halo.
10. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da p je jednak 1.
11. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R2 je alkiloksi ili alkiltio.
12. Uporaba prema zahtjevu 10 naznačena time da R2 je C1-4alkiloksi.
13. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R3 je Ar, Het, Ar-alkil ili Het-alkil.
14. Uporaba prema bilo kojem od zahtjeva 1 do 11 naznačena time da R3 je C1-4alkil, naftil, fenil proizvoljno supstituiran sa alkilom ili alkiloksi, piridinilom, benzo[1,3]dioksolilom, -CH2-(CH2)n-R3a pri čemu R3a je cikloheksil, fenil, naftil ili furanil, R3a je proizvoljno supstituiran sa alkilom, te pri čemu n je 0 ili 1.
15. Uporaba prema zahtjevu 13 naznačena time da R3 je naftil ili fenil.
16. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da su R4 i R5 svaki neovisno vodik ili C1-4alkil.
17. Uporaba prema bilo kojem od zahtjeva 1 do 14 naznačena time da R4 i R5 zajedno i uključujući N na kojeg su spojeni tvore radikal koji je odabran iz skupine koja sadrži pirolidinil, piperidinil, piperazinil ili morfolinil, koji su proizvoljno supstituirani sa alkilom, amino ili mono-ili di(alkil)amino.
18. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R6 je vodik ili halo.
19. Uporaba prema bilo kojem od zahtjeva 1 do 16 naznačena time da R6 je vodik.
20. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da r je jednak 1.
21. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da R7 je vodik.
22. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da spoj je spoj prema formuli (Ia).
23. Uporaba prema zahtjevu 1 naznačena time da spoj je spoj prema formuli (Ia) pri čemu R1 je vodik, halo, alkil, Ar ili Het; p = 1; R2 je alkiloksi, alkiltio ili radikal sa formulom
[image]
R3 je alkil, Ar, Het, Ar-alkil ili Het-alkil; q = 1, 2 ili 3; R4 i R5 svaki neovisno su vodik, alkil ili benzil; ili R4 i R5 zajedno i uključujući N na kojeg su spojeni tvore radikal koji je odabran iz skupine koja sadrži pirolidinil, piperidinil, piperazinil ili morfolinil, proizvoljno supstituiran sa alkilom ili mono-ili di(alkil)amino; R6 je vodik, halo, alkiloksi, alkil ili fenil proizvoljno supstituiran sa alkiloksi; r je jednak 1 ili 2; R7 je vodik.
24. Uporaba prema zahtjevu 1 naznačena time da je spoj odabran od slijedećih spojeva
[image]
[image]
[image]
njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov stereokemijski izomerni oblik, njegov tautomerni oblik ili njegov N-oksid.
25. Uporaba prema bilo kojem od prethodnih zahtjeva naznačena time da bakterijska infekcija je infekcija sa gram-pozitivnom bakterijom.
26. Uporaba prema zahtjevu 24 naznačena time da gram-pozitivna bakterija je Staphylococcus aureus ili Streptococcus pneumoniae.
27. Spoj naznačen time da spoj je odabran od
[image]
[image]
[image]
njegova farmaceutski prihvatljiva kisela ili bazna adicijska sol, njegov tautomerni oblik ili njegov N-oksid.
28. Kombinacija naznačena time da se sastoji od (a) spoja sa formulom (Ia) ili (Ib) kako je definirano u bilo kojem od prethodnih zahtjeva, i (b) jednog ili više drugih antibakterijskih sredstava pod uvjetom da su jedno ili više drugih antibakterijskih sredstava različita od antimikobakterijskih sredstava.
29. Farmaceutski pripravak naznačen time da sadrži farmaceutski prihvatljiv nosač, te kao aktivni sastojak, terapeutski učinkovitu količinu (a) spoja sa formulom (Ia) ili (Ib) kako je definirano u bilo kojem od zahtjeva 1 do 26, te (b) jedno ili više drugih antibakterijskih sredstava pod uvjetom da su jedno ili više drugih antibakterijskih sredstava različita od antimikobakterijskih sredstava.
30. Uporaba kombinacije prema zahtjevu 27 ili farmaceutskog pripravka prema zahtjevu 28 naznačena time da je za liječenje bakterijske infekcije.
31. Proizvod koji sadrži (a) spoj sa formulom (Ia) ili (Ib) kako je definirano u bilo kojem od zahtjeva 1 do 26, i (b) jedno ili više drugih antibakterijskih sredstava pod uvjetom da su jedno ili više drugih antibakterijskih sredstava različita od antimikobakteriskih sredstava, naznačen time da se koristi kao kombinirani pripravak za istovremenu, odvojenu ili slijednu uporabu kod liječenja bakterijske infekcije.
32. Spoj sa formulom
[image]
naznačen time da W2 predstavlja halo, i R1, R2, R3, R6, R7, q, p i r su kako je definirano u zahtjevu 1.
33. Spoj sa formulom
[image]
naznačen time da W2 predstavlja halo, i R1, R3, R6, R7, R8, R9, q, p i r su kako je definirano u zahtjevu 1.
34. Postupak za pripremu spoja sa formulom (Ia), naznačen time da intermedijer sa formulom (IV) reagira sa pogodnim aminom sa formulom HNR4R5 u prisutnosti CO i H2, nekog pogodnog katalizatora, proizvoljno drugog katalizatora, pogodnog liganda i pogodnog otapala
[image]
pri čemu R1, R2, R3, R4, R5, R6, R7, p i r su kako je definirano u zahtjevu 1 i pri čemu q je 0, 1 ili 2.
35. Uporaba prema bilo kojem od zahtjeva 1 do 24 i 29 naznačena time da bakterijska infekcija je infekcija sa stafilokokom, enterokokom ili streptokokom.
36. Uporaba prema bilo kojem od zahtjeva 1 do 24 i 29 naznačena time da bakterijska infekcija je infekcija sa Staphylococcus aureus (MRSA) koja je otporna na meticilin, koagulaza-negativnim stafilokokom (MRCNS) koji je otporan na meticilin, Streptococcus pneumoniae koja je otporna na penicilin ili višestruko otpornom Enterococcus faecium.
37. Uporaba prema bilo kojem zahtjevu od 1 do 25 i 29 naznačena time da bakterijska infekcija je infekcija sa Staphylococcus aureus (MRSA) koja je otporna na meticilin.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05105762 | 2005-06-28 | ||
| PCT/EP2006/063553 WO2007000435A1 (en) | 2005-06-28 | 2006-06-26 | Quinoline derivatives as antibacterial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120912T1 true HRP20120912T1 (hr) | 2012-12-31 |
Family
ID=34940244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120912TT HRP20120912T1 (hr) | 2005-06-28 | 2012-11-13 | Derivati kinolina kao antibakterijska sredstva |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US8841321B2 (hr) |
| EP (1) | EP1898914B1 (hr) |
| JP (1) | JP5193858B2 (hr) |
| KR (1) | KR101329585B1 (hr) |
| CN (1) | CN101247811B (hr) |
| AP (1) | AP2386A (hr) |
| AR (1) | AR054626A1 (hr) |
| AU (1) | AU2006263883B2 (hr) |
| BR (1) | BRPI0612498A8 (hr) |
| CA (1) | CA2612619C (hr) |
| CY (1) | CY1113579T1 (hr) |
| DK (1) | DK1898914T3 (hr) |
| EA (1) | EA014423B1 (hr) |
| ES (1) | ES2393203T3 (hr) |
| HK (1) | HK1122730A1 (hr) |
| HR (1) | HRP20120912T1 (hr) |
| IL (1) | IL188393A0 (hr) |
| JO (1) | JO2752B1 (hr) |
| ME (1) | ME01484B (hr) |
| MX (1) | MX2008000081A (hr) |
| MY (1) | MY153291A (hr) |
| NO (1) | NO342701B1 (hr) |
| NZ (1) | NZ564379A (hr) |
| PA (1) | PA8683801A1 (hr) |
| PL (1) | PL1898914T3 (hr) |
| PT (1) | PT1898914E (hr) |
| RS (1) | RS52517B (hr) |
| SI (1) | SI1898914T1 (hr) |
| TW (1) | TWI387457B (hr) |
| UA (1) | UA92175C2 (hr) |
| WO (1) | WO2007000435A1 (hr) |
| ZA (1) | ZA200711165B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2970B1 (en) | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| KR102110366B1 (ko) | 2012-04-27 | 2020-05-14 | 얀센 파마슈티카 엔.브이. | 항균성 퀴놀린 유도체 |
| AU2013254674B2 (en) | 2012-04-27 | 2017-02-02 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
| CN107001272A (zh) | 2014-12-23 | 2017-08-01 | 阿尔比马尔公司 | 用于合成烷基化甲吡酮类似物的一步法 |
| CN106928139B (zh) * | 2017-05-08 | 2019-06-25 | 福建省微生物研究所 | 一种贝达喹啉杂质的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19937116A1 (de) * | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin Kochsalzformulierung |
| UA82198C2 (uk) * | 2002-07-25 | 2008-03-25 | Янссен Фармацевтика Н.В. | Хінолінові похідні та їх використання як мікобактеріальних інгібіторів, спосіб їх одержання, фармацевтична композиція на їх основі, проміжна сполука |
| SI1675852T1 (sl) | 2003-09-22 | 2009-06-30 | Janssen Pharmaceutica Nv | 7-amino alkilidenil-heterociklični kinoloni in naftiridoni |
| JO2524B1 (en) * | 2004-05-28 | 2010-03-17 | جانسن فارمسيتكا ان في | Use of substituted quinoline derivatives to treat drug-resistant microbial diseases |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| UA88701C2 (ru) | 2005-06-28 | 2009-11-10 | Янссэн Фармацэвтика Н.В. | Производные хинолина как антибактериальные агенты |
-
2006
- 2006-06-25 JO JO2006188A patent/JO2752B1/en active
- 2006-06-26 EA EA200800154A patent/EA014423B1/ru unknown
- 2006-06-26 ME MEP-2012-127A patent/ME01484B/me unknown
- 2006-06-26 MX MX2008000081A patent/MX2008000081A/es active IP Right Grant
- 2006-06-26 KR KR1020087002107A patent/KR101329585B1/ko active IP Right Grant
- 2006-06-26 WO PCT/EP2006/063553 patent/WO2007000435A1/en active Application Filing
- 2006-06-26 SI SI200631468T patent/SI1898914T1/sl unknown
- 2006-06-26 NZ NZ564379A patent/NZ564379A/en not_active IP Right Cessation
- 2006-06-26 ES ES06763889T patent/ES2393203T3/es active Active
- 2006-06-26 RS RS20120480A patent/RS52517B/en unknown
- 2006-06-26 PT PT06763889T patent/PT1898914E/pt unknown
- 2006-06-26 PL PL06763889T patent/PL1898914T3/pl unknown
- 2006-06-26 CA CA2612619A patent/CA2612619C/en not_active Expired - Fee Related
- 2006-06-26 AU AU2006263883A patent/AU2006263883B2/en not_active Ceased
- 2006-06-26 UA UAA200714927A patent/UA92175C2/ru unknown
- 2006-06-26 DK DK06763889.0T patent/DK1898914T3/da active
- 2006-06-26 EP EP06763889A patent/EP1898914B1/en active Active
- 2006-06-26 AP AP2008004303A patent/AP2386A/xx active
- 2006-06-26 BR BRPI0612498A patent/BRPI0612498A8/pt not_active Application Discontinuation
- 2006-06-26 CN CN2006800310552A patent/CN101247811B/zh not_active Expired - Fee Related
- 2006-06-26 US US11/993,145 patent/US8841321B2/en not_active Expired - Fee Related
- 2006-06-26 JP JP2008518810A patent/JP5193858B2/ja not_active Expired - Fee Related
- 2006-06-27 TW TW095123127A patent/TWI387457B/zh not_active IP Right Cessation
- 2006-06-27 MY MYPI20063044A patent/MY153291A/en unknown
- 2006-06-28 AR ARP060102787A patent/AR054626A1/es unknown
- 2006-06-28 PA PA20068683801A patent/PA8683801A1/es unknown
-
2007
- 2007-12-20 ZA ZA2007/11165A patent/ZA200711165B/en unknown
- 2007-12-25 IL IL188393A patent/IL188393A0/en active IP Right Grant
-
2008
- 2008-01-28 NO NO20080501A patent/NO342701B1/no not_active IP Right Cessation
- 2008-12-24 HK HK08113967.4A patent/HK1122730A1/xx not_active IP Right Cessation
-
2012
- 2012-11-13 HR HRP20120912TT patent/HRP20120912T1/hr unknown
- 2012-11-14 CY CY20121101090T patent/CY1113579T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20131116T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20160585T1 (hr) | Antibakterijski derivati kinolina | |
| HRP20120912T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20170044T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20120910T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20140206T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| JP2009503024A5 (hr) | ||
| HRP20110392T1 (hr) | Derivati kinolina za liječenje latentne tuberkuloze | |
| HRP20161704T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| JP2009503025A5 (hr) | ||
| CA2566544A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| AR040673A1 (es) | Inhibidores micobacterianos, composicion farmaceutica y proceso de preparacion del compuesto | |
| CA2554049A1 (en) | Quinoline derivatives for use as mycobacterial inhibitors | |
| JP2010511668A5 (hr) | ||
| HRP20100696T1 (hr) | Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini | |
| TW200744595A (en) | Quinoline derivatives as antibacterial agents | |
| JP2009514894A5 (hr) | ||
| JP2008546824A5 (hr) | ||
| HRP20100428T1 (hr) | Antibakterijski derivati kvinolina | |
| IL189017A0 (en) | 8-methoxy-9h-isothiazolo[5,4-b]quinoline-3,4-diones and related compounds as anti-effective agents | |
| JP2009503021A5 (hr) | ||
| NZ595448A (en) | Hydroxythienoquinolones and related compounds as anti-infective agents | |
| JP2010511667A5 (hr) | ||
| JP2008543964A5 (hr) | ||
| HRP20110540T1 (hr) | Antibakterijski derivati kinolina |